by Mr. Market to this news after close yesterday:SAN FRANCISCO (MarketWatch) -- Genentech Inc. late Wednesday posted a 41% rise in second-quarter profit that was powered by higher sales of its marquee cancer drugs, including a 33% surge in sales of Avastin.There must have been an expectation already priced in...-ffnew to DNA watching
Best Of |
Favorites & Replies |
Start a New Board |
My Fool |
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar